Click on highlighted book title for details. Some books can be purchased through our affiliate, Amazon.com. Click on the title for more information and Amazon.com purchase button.
A Maverick’s Odyssey: One Doctor’s Quest to Conquer Disease: The Story of Stephen L. DeFeflice, M.D. and FIM, the Foundation for Innovation in Medicine
by Michael Mannion
Regulation of Functional Foods and Nutraceuticals
Editor, Clair Hessler, IFT Press, 2005
Chapter 12 “The Nutraceutical Health Sector: A Point of View” was written by Stephen L. DeFelice, M.D.
- The Carnitine Defense
Stephen L. DeFelice, M.D., Rodale Books,
- Visit the publisher’s website here
- Consumed Why Americans Love, Hate and Fear Food
Michelle Stacey, Simon & Schuster, New York, London, Toronto, Sydney, Tokyo, Singapore, 1994
- Contains “Eating Your Medicine – The Battle Over Superfoods,” a chapter refering to Stephen L. DeFelice, M.D. which can be read here on-line.
- Drug Discovery The Pending Crisis
Stephen L. DeFelice, M.D., Medcom Press
From Oysters to Insulin
Nature & Medicine at Odds
Stephen L. DeFelice, M.D., Citadel Press, Secaucus, New Jersey 1986
Description of book
La revolution nutraceutique, la redecouvert medicale des substances naturelles
Stephen L. DeFelice, M.D., Frishon Roche
This book is a French translation of From Oysters to Insulin with an international analysis by Professor Andre Rougereau, President L’Lnstitut de Nutrition.
- Memory Loss Normal vs. Abnormal
Stephen L. DeFelice, M.D. & Sue Nirenberg, Lyle Stuart., 1987
Nutraceuticals Developing, Claiming, and Marketing Medical Foods
Edited by Stephen L. DeFelice, M.D., Marcel Decker, Inc., 2002
Visit the publisher’s web site here or go directly to the publisher’s page about this book at: http://www.dekker.com/cgi-bin/webdbc/md/detail.htx?d_cat_id=0107-0
- Orphan Drugs
Edited by Fred E. Karch, M.D., Marcel Decker, Inc., 1982
Visit the publisher’s web site at:http://www.dekker.com
Or go directly to the publisher’s page about this book at: http://www.dekker.com/cgi-bin/webdbc/md/detail.htx?d_cat_id=1681-7
Orphan Drugs examines, in detail, a complex, often frustrating question-why is it that many useful drugs are not available for the patients who need them? The developers of these drugs are unable to attract enough financial support from pharmaceutical manufacturers or federal agencies to fully test their discoveries. This innovative book illustrates the factors that lead to orphan status and presents model programs for their adoption. Contains “The Carnitine Story,” a chapter by Stephen L. DeFelice which can be read here on-line.
(© 2009 The Foundation For Innovation In Medicine. All rights reserved.)